Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Rapid multiplex PCR on bronchoalveolar lavage to guide antibiotics for ventilator-associated pneumonia

Official title: Fast Multiplex PCR of Bronchoalveolar Lavage for Antibiotic Stewardship in Ventilator Associated Pneumonia. A Multicenter, Randomized Controlled Study

Run by CHU de Reims · NCT06554327 · Data updated 2026-11-12

This trial tests whether using a fast multiplex PCR on bronchoalveolar lavage samples helps doctors choose the right antibiotics sooner for adults on mechanical ventilation suspected of ventilator-associated pneumonia.

More Ventilator Associated Pneumonia trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment265 (estimated)
SponsorCHU de Reims
Academic / other
Locations1 site (Reims)
StatusRecruiting
StartedMarch 6, 2025
Main results expectedSeptember 6, 2030
Study endsOctober 4, 2030
Registry record updatedSeptember 3, 2026
Trial IDNCT06554327 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adult ICU patients on mechanical ventilation for at least 48 hours with suspected VAP who have an indication for bronchoalveolar lavage and meet consent and coverage requirements.

Probably not a fit

Patients who will not have bronchoalveolar lavage, those intubated less than 48 hours, those with a prior VAP during the same hospital stay, pregnant patients, or patients under legal protection/no social security are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized controlled trial in eight university intensive care units in the Grand-Est region of France comparing multiplex PCR plus standard bacterial culture versus bacterial culture alone for suspected VAP. The multiplex test used is the BioFire FilmArray Pneumonia Panel Plus, performed on bronchoscopic bronchoalveolar lavage fluid and able to detect multiple bacterial DNA targets and resistance genes. Standard culture and susceptibility results typically take 48–72 hours, while the PCR gives much faster results that could inform empirical antibiotic choices. The primary comparison is the percentage of appropriate empirical antibiotic therapy in patients with culture-confirmed VAP.

Why it matters

Potential benefit: If successful, the approach could let clinicians choose more appropriate antibiotics sooner, reducing unnecessary broad-spectrum use and potentially improving patient outcomes.

How similar studies have gone: Prior work shows multiplex PCR panels detect pathogens and resistance markers faster than culture, but clinical trials have produced mixed results on whether that speed consistently translates into more appropriate antibiotic use or better outcomes in ICUs.

Who can join: the full rules

Show full inclusion / exclusion criteria
inclusion criteria :

* Adult patients, hospitalized in intensive care unit
* on mechanical ventilation for at least 48 hours
* Suspected VAP
* With an indication for bronchoalveolar lavage (BAL)

exclusion criteria :

* Patients under legal protection or without social security coverage
* Pregnant women
* Previous episode of VAP during the same hospitalization

Where it's running

  • Damien JOLLY
    Reims, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.